- Home
- CCEL vs RFL Comparison
CCEL vs RFL Comparison
Compare CCEL & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- RFL
- Stock Information
- Founded
- CCEL 1989
- RFL 2017
- Country
- CCEL United States
- RFL United States
- Employees
- CCEL N/A
- RFL N/A
- Industry
- CCEL Managed Health Care
- RFL Real Estate
- Sector
- CCEL Health Care
- RFL Finance
- Exchange
- CCEL Nasdaq
- RFL Nasdaq
- Market Cap
- CCEL 50.0M
- RFL 55.3M
- IPO Year
- CCEL 1997
- RFL N/A
- Fundamental
- Price
- CCEL $7.80
- RFL $1.79
- Analyst Decision
- CCEL
- RFL
- Analyst Count
- CCEL 0
- RFL 0
- Target Price
- CCEL N/A
- RFL N/A
- AVG Volume (30 Days)
- CCEL 13.9K
- RFL 25.8K
- Earning Date
- CCEL 12-24-2024
- RFL 12-27-2024
- Dividend Yield
- CCEL 3.14%
- RFL N/A
- EPS Growth
- CCEL N/A
- RFL N/A
- EPS
- CCEL N/A
- RFL N/A
- Revenue
- CCEL $31,838,476.00
- RFL $697,000.00
- Revenue This Year
- CCEL $3.97
- RFL N/A
- Revenue Next Year
- CCEL $0.91
- RFL N/A
- P/E Ratio
- CCEL N/A
- RFL N/A
- Revenue Growth
- CCEL 1.95
- RFL 151.62
- 52 Week Low
- CCEL $4.47
- RFL $1.29
- 52 Week High
- CCEL $9.50
- RFL $2.50
- Technical
- Relative Strength Index (RSI)
- CCEL 45.13
- RFL 45.87
- Support Level
- CCEL $7.60
- RFL $1.74
- Resistance Level
- CCEL $9.10
- RFL $1.92
- Average True Range (ATR)
- CCEL 0.27
- RFL 0.09
- MACD
- CCEL -0.15
- RFL -0.00
- Stochastic Oscillator
- CCEL 23.61
- RFL 40.91
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.